Atavistik Bio’s high-throughput platform for the unbiased identification of metabolite-protein interactions, will enable us to discover first-in-class drugs inspired and empowered by nature’s own mechanisms of allosteric control. Our unique approach marries this validated platform with structure-aided drug design capabilities and cutting-edge insights into the regulation of metabolic systems—including clinical metabolomic data sets—to apply to genetically-validated targets in metabolic diseases and cancer.
Leadership

Marion Dorsch, PhD
President & CSO

Jeff Goater
Interim CEO
Founders

Jared Rutter, PhD
Professor of Biochemistry
University of Utah
University of Utah
HHMI Investigator

Ralph J DeBerardinis, MD, PhD
Professor, Children’s Research Institute
University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
HHMI Investigator
Board of Directors
John Josey, PhD
Helen Hobbs, MD
Adam Goulburn, PhD
Chairman
The Column Group
The Column Group
Helen Hobbs, MD
University of Texas Southwestern Medical Center
HHMI Investigator
HHMI Investigator
Adam Goulburn, PhD
Lux Capital
Jeff Goater
Thilo Schroeder, PhD
Interim CEO
The Column Group
The Column Group
Thilo Schroeder, PhD
Nextech
News
August 24, 2021
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
Careers
Join our team as we expand into our new Cambridge-based location.
Investors


